ÂÜÀòÂÒÂ×

Greg Fralish currently serves as Chief Business Officer at GlycoEra AG and holds the position of Vice President, Head of Corporate Development at 2seventy bio. Previously, Fralish was Vice President of Oncology Corporate Development at bluebird bio and Head of Oncology Business Development at Takeda. As Co-Founder, President, and CEO of Ziel Bio, Fralish played a pivotal role in establishing the company and advancing its clinical studies. Fralish also contributed significantly as Head of Translational Science at the University of Virginia School of Medicine and as Program Director at Cato BioVentures. Earlier experience includes roles at Cato Research and as a post-doctoral fellow at Duke University. Fralish earned a PhD in Biochemistry from The University of Georgia.